2023 annual financial data
ImmunityBio 2023 Operating cash flow margin
Direct answer
Operating cash flow margin was -58,964.15%.
Operating income was -362,250,000 USD and net income was -583,196,000 USD.
Operating cash flow was -366,757,000 USD.
Get free ImmunityBio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 622,000 USD
- Operating income
- -362,250,000 USD
- Net income
- -583,196,000 USD
- Operating cash flow
- -366,757,000 USD